NASDAQ / LIVE COMPANY INTELLIGENCE

Entrada Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERTRDA
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / TRDA COVERAGE

What’s moving Entrada Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Investors are testing whether Entrada Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

The story matters when it changes Entrada Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates

Investors are testing whether Entrada Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The story matters when it changes Entrada Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
What You Need To Know About Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Investor Composition

What You Need To Know About Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Investor Composition

The story matters when it changes Entrada Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest TRDA filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-05 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-02-26 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-08-05 · Period 2026-08-05SEC ↗8-KMaterial company eventFiled 2026-06-10 · Period 2026-06-10SEC ↗8-KMaterial company eventFiled 2026-05-19 · Period 2026-05-18SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-24 · Period 2026-06-10SEC ↗4Official SEC filingFiled 2026-08-03 · Period 2026-07-30SEC ↗
EARNINGS / QUARTERLY TRACKER

Entrada Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.